#155092

Anti-AvW-15 (von Willebrand Factor) [MBC 122.6]

Cat. #155092

Anti-AvW-15 (von Willebrand Factor) [MBC 122.6]

Cat. #: 155092

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: von Willebrand Factor

Class: Monoclonal

Application: ELISA ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Versiti Blood Research Institute

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-AvW-15 (von Willebrand Factor) [MBC 122.6]
  • Alternate name: vWf
  • Research fields: Immunology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Purpose: Marker
  • Conjugation: Unconjugated
  • Molecular weight: 250 kDa
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; WB
  • Description: Von Willebrand factor (vWF) is a multimeric glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII). Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding.
  • Immunogen: R/A (reduced and alkylated) fragment of vWF (see notes column)
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: IgG1

Target Details

  • Target: von Willebrand Factor
  • Molecular weight: 250 kDa
  • Tissue cell line specificity: Mouse
  • Target background: Von Willebrand factor (vWF) is a multimeric glycoprotein that functions in hemostasis as the initiator of platelet adhesion at the site of vascular injury and as the carrier of the anti-hemophilic factor, factor VIII (FVIII). Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding.

Applications

  • Application: ELISA ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Flood et al. 2018. Res Pract Thromb Haemost. 2(2):390-398. PMID: 30046743.
  • Doruelo et al. 2017. J Thromb Haemost. 15(8):1559-1566. PMID: 28544236.
  • Roberts et al. 2016. Blood. 127(20):2472-80. PMID: 26917779.
  • Flood et al. 2015. Blood. 125(14):2297-304. PMID: 25662333.
  • Flood et al. 2013. Clin Chem. 59(4):684-91. PMID: 23340442.
  • Jacobi et al. 2012. Blood. 119(19):4543-53. PMID: 22431572.
  • Flood et al. 2011. Blood. 117(6):e67-74. PMID: 21148813.